Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

This pilot trial is testing whether riluzole — a medication already approved for ALS (Lou Gehrig's disease) — can prevent or reduce "chemo brain," the memory and thinking problems that many cancer patients experience during and after chemotherapy. The study focuses on patients receiving specific chemotherapy drugs (anthracycline- or platinum-based). **You may be eligible if:** - You have been diagnosed with cancer and are about to start chemotherapy that includes an anthracycline (like doxorubicin) or a platinum drug (like cisplatin or carboplatin) - You are 18 years of age or older - Your life expectancy is greater than 6 months - You are able to complete questionnaires and cognitive assessments **You may NOT be eligible if:** - You have a primary brain tumor or cancer that has spread to the brain - You are pregnant, breastfeeding, or planning to become pregnant during the study - You have a known allergy to riluzole - You are a current smoker or are taking certain medications that interact with riluzole (such as pixantrone) - You are unwilling to complete the neuropsychological testing required Talk to your doctor to see if this trial is right for you.